Table 1.

Baseline characteristics by treatment group

CharacteristicMonthly ErgocalciferolWeekly ErgocalciferolPlacebo
Patients (n)333636
Age (yr)58±1653±1759±17
Men (%)28 (84.9)25 (69.4)29 (80.6)
Race (%)
 White21 (63.6)23 (63.9)22 (61.1)
 Black9 (27.3)13 (36.1)9 (25.0)
 Asian2 (6.1)0 (0.0)4 (11.1)
 Multiple-race1 (3.0)0 (0.0)1 (2.8)
Ethnicity (%)
 Hispanic5 (15.2)4 (11.1)6 (16.7)
 Non-Hispanic28 (84.9)32 (88.9)30 (83.3)
Vascular access (%)
 Arterial venous fistula10 (30.3)11 (30.6)11 (30.6)
 Arterial venous graft1 (3.0)3 (8.3)3 (8.3)
 Catheter22 (66.7)22 (61.1)22 (61.1)
Vital signs
 Body mass index (kg/m2)32.0±9.530.5±9.830.1±6.5
 Systolic BP (mmHg)146±22146±28145±27
 Diastolic BP (mmHg)77±1681±1975±17
 Heart rate (beats/min)75±1077±1378±14
Laboratory values
 Calcium (mg/dl)8.7±0.68.8±0.78.8±0.7
 Creatinine (mg/dl)5.0 (3.0, 6.7)6.0 (4.2, 7.4)5.4 (3.7, 6.7)
 Alkaline phosphatase (IU/L)75.5 (54.0, 103.0)77.5 (52.0, 107.0)87.0 (68.0, 115.0)
 Albumin (g/dl)3.4±0.63.5±0.53.6±0.5
 PTH (pg/ml)253.0 (160.0, 338.0)265.0 (169.5, 492.5)248.5 (155.0, 382.5)
 Phosphate (mg/dl)4.2±1.14.2±1.54.1±1.0
 White blood count (×109/L)7.2±2.27.4±2.47.8±2.6
 Hemoglobin (g/dl)9.5±1.38.7±1.79.3±1.0
 TIBC (µg/dl)244.4±43.7241.0±65.3226.2±41.4
 Iron (µg/dl)57.0 (40.0, 67.0)60.0 (45.0, 85.0)45.0 (26.0, 61.0)
 Ferritin (ng/ml)157.0 (107.0, 235.0)187.0 (93.0, 349.0)203.0 (113.5, 332.5)
 Urea reduction ratio (%)71.5±10.066.6±8.671.2±9.9
 25(OH)D (ng/ml)22.3±6.521.8±7.021.7±7.3
 25(OH)D2 (ng/ml)6.4±7.57.6±8.06.0±8.1
 25(OH)D3 (ng/ml)16.2±7.914.2±8.215.6±7.4
Medication
β-blocker (%)23 (69.7)30 (83.3)28 (77.8)
 ACE inhibitor (%)7 (21.2)4 (11.1)5 (13.9)
  • Values are expressed as mean±SD, median (Q1, Q3), or n (%). PTH, parathyroid hormone; TIBC, total iron binding capacity; ACE, angiotensin-converting enzyme; 25(OH)D, 25-hydroxyvitamin D.